Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 9/20 | 0.68 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.68 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.68 |
| ▸ | LGALS7; LGALS7B | P47929 | 4/20 | 0.62 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.62 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.60 |
| ▸ | CD69 | Q07108 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681107 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL19976159 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13839152 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL16258790 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL17678835 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL5357606 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL23613765 | 0.96 | LGALS3 (0.64) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL26334737 | 0.96 | LGALS3 (0.64) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL16407357 | 0.96 | LGALS3 (0.64) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 | |
| SCHEMBL9566129 | 0.94 | CD69 (0.60) | LGALS3LGALS8LGALS4LGALS7; LGALS7BLGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230096-B2 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20040147730-A1 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1353934-A1 | NEW INHIBITORS AGAINST GALECTINS | Nilsson, Ulf (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002057284-A1 | NEW INHIBITORS AGAINST GALECTINS | NILSSON ULF (SE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147730-A1 | Inhibitors against galectins | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS8 6/4885LGALS4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.